<DOC>
	<DOCNO>NCT00803933</DOCNO>
	<brief_summary>Human African Trypanosomiasis sleeping sickness make spectacular return last decade , many place demand largely surpasses capacity treatment center . Treatment disease remain unsatisfactory . All currently use drug must administer parenterally , treatment lengthy , adverse drug reaction frequent . There currently drug easily administer low toxicity , might thus use tool support disease control . This study aim compare safety efficacy DB289 , new , orally administer dication prodrug pentamidine i.m . injection treatment first stage sleep sickness . The project execute framework international consortium consist several partner academia , industry Democratic Republic Congo Ministries Health .</brief_summary>
	<brief_title>Trial DB289 Treatment Stage I African Trypanosomiasis</brief_title>
	<detailed_description />
	<mesh_term>Trypanosomiasis , African</mesh_term>
	<mesh_term>Trypanosomiasis</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<mesh_term>Pentamidine</mesh_term>
	<criteria>1 . The patient early stage T. b. gambiense infection i.e . parasitologically confirmed infection blood lymph node aspirate great equal 5 WBC mm3 detect CSF microscopic examination 2 . Patient 15 50 year old 3 . Patient minimal weight 35 kilogram 4 . If patient female child bear potential ( woman consider nonchild bear potential post menopausal 2 year hysterectomy ) : 1. lactating , 2. negative urine pregnancy test result within 24 hour prior DB289 treatment 3. agrees use medically proven method contraception ( abstinence sexual intercourse acceptable method ) day consent end observation period ( day 7 ) . 5 . Patient understood sign Informed Consent . If patient minor , legal guardian sign Informed Consent 1 . The patient late stage T.b . gambiense infection i.e . presence parasite CSF upon microscopic examination WBC count &gt; 5mm1 2 . Active clinically relevant medical condition Investigator opinion may jeopardize subject safety interfere participation study , include limited : significant liver disease , chronic pulmonary disease , significant cardiovascular disease , diabetes , thyroid disease , gout , infection include know HIV infection , CNS trauma seizure disorder ( A list typical sign symptom provide guidance investigator attachment 1 ) 3 . Coma Score less 9 Glasgow Coma Scale ( Appendix 8 ) 4 . Withdrawal consent time study 5 . Any condition compromise ability communicate investigator require completion study . 6 . The subject previously treat African Trypanosomiasis . 7 . The subject previously enrol study .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>first stage</keyword>
	<keyword>Trypanosoma brucei gambiense</keyword>
	<keyword>T. b. gambiense</keyword>
	<keyword>sleep sickness</keyword>
	<keyword>First stage T. b. gambiense sleep sickness</keyword>
</DOC>